Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North Carolina company, could soon be facing generic competition. Inspire said in a regulatory filing that generics company Sandoz notified the company that it has submitted […]
Inspire Pharmaceuticals (NASDAQ:ISPH) CEO Adrian Adams joined the North Carolina company in the winter of 2010 with goals of expanding its business beyond eye products and commercializing a breakthrough cystic fibrosis treatment. In January, one month shy of Adams one-year anniversary at Inspire’s helm and days removed from announcing a failed clinical trial on the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Merck (NYSE:MRK) is acquiring Raleigh, North Carolina-based Inspire Pharmaceuticals (NASDAQ:ISPH) for $430 million under a definitive agreement announced Tuesday. Under the agreement, a Merck subsidiary will commence a tender offer for all outstanding shares of Inspire at a price of $5 per share cash. That’s 26 percent more than Inspire’s April 4 close of $3.98. […]
Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023. Raleigh, North Carolina-based Inspire disclosed in a securities filing that the extension gives one Diquas patent an additional five years of exclusivity; another patent received approximately 4.5 years of exclusivity. […]